Asia Green Biotechnology

Asia Green Biotechnology EV/FCF

Delisted·Sep 23, 2026

The EV/FCF (Enterprise Value to Free Cash Flow) of Asia Green Biotechnology (ASIA.CN) as of Nov 15, 2026 is -15.24. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -4.81 — a change of 216.64% (lower).

EV/FCF

-15.24

YoY

216.64%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Asia Green Biotechnology is 2023 -15.24 . EV/FCF (Enterprise Value to Free Cash Flow) of Asia Green Biotechnology was 2022 -4.81 . It decreases by 216.64% lower compared to the previous year.

The Asia Green Biotechnology EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-6.76 CAD
Jan 1, 2019
-0.82 CAD
Jan 1, 2020
-0.86 CAD
Jan 1, 2021
-1.51 CAD
Jan 1, 2022
-4.81 CAD
Jan 1, 2023
-15.24 CAD
The Asia Green Biotechnology EV/FCF history
YEAREV/FCFYoY
-15.24+216.64%
-4.81+218.93%
-1.51+75.81%
-0.86+4.66%
-0.82-87.86%
-6.76—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Asia Green Biotechnology Stock analysis

What does Asia Green Biotechnology do? Asia Green Biotechnology Corp develops and supplies proprietary organic hybridization technology for agri-technology applications. The company partners with InPlanta Biotechnology Inc. for hemp cultivation under a license agreement, and collaborates with Swysh Inc. and Pathway Rx Corp for cannabinoid extract development. Revenue is generated through the supply of technology and related products, with operations expanding in Cambodia and Thailand through R&D programs. The firm focuses on commercial hemp and cannabinoid product development under licensed agreements. The company's primary market segments include agricultural technology providers and medicinal cannabinoid extract buyers. InPlanta Biotechnology Inc. licenses hemp cultivation, while Swysh Inc. and Pathway Rx Corp. license cannabinoid extract development. Asia Green Biotechnology Corp. supplies technology and manages the commercialization of these products derived from its organic hybridization technology. Asia Green Biotechnology Corp. operates under license agreements with InPlanta Biotechnology Inc., Swysh Inc., and Pathway Rx Corp. to develop and supply hemp and cannabinoid products. The company's revenue streams come from technology supply and product commercialization under these agreements, with R&D programs in Cambodia and Thailand supporting future market expansion. Asia Green Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Asia Green Biotechnology stock

EV/FCF (Enterprise Value to Free Cash Flow) of Asia Green Biotechnology is -15.24 in 2023.

EV/FCF (Enterprise Value to Free Cash Flow) of Asia Green Biotechnology changed from -4.81 to -15.24, representing a 216.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Asia Green Biotechnology since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Asia Green Biotechnology with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Asia Green Biotechnology

All Key Metrics — Asia Green Biotechnology